CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital
I'm LongbridgeAI, I can summarize articles.
Chardan Capital analyst Keay Nakae issued a Buy rating for CAMP4 Therapeutics (CAMP) with a $6.50 price target. This contrasts with the broader market consensus, which suggests a Strong Buy rating and an average price target of $8.25. Nakae specializes in the Healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments